Immunogenicity and safety of an indigenously developed DTPw hepatitis B combination vaccine in Indian infants

Raju Shah1, M B Raghu, A Shivananda

  • 1Department of Pediatrics, Shardaben General Hospital and Smt NHL Municipal Medical College, Ahmedabad, India. rajucshah@gmail.com

Indian Pediatrics
|October 25, 2008
PubMed

Insights

This study found the indigenous Shantetra vaccine (diphtheria, tetanus, pertussis, and hepatitis B) to be safe and effective in Indian infants. It demonstrated high seroprotective immune responses comparable to Tritanrix HB, with similar mild adverse events.

Area of Science:

  • Pediatric Vaccinology
  • Immunology
  • Infectious Disease Prevention

Background:

  • Hepatitis B, diphtheria, tetanus, and B. pertussis (pertussis) infections pose significant health risks to infants.
  • Effective vaccination strategies are crucial for preventing these diseases in early childhood.
  • Indigenous vaccine development is vital for public health accessibility and sustainability.

Purpose of the Study:

  • To assess the safety and immunogenicity of an indigenous tetravalent vaccine (Shantetra) against hepatitis B, diphtheria, tetanus, and B. pertussis.
  • To compare the efficacy of Shantetra with a licensed comparator vaccine (Tritanrix HBTM) in Indian infants.

Main Methods:

  • A multicentric, randomized, single-blind, intention-to-treat study was conducted across five tertiary care centers in India.
  • 151 healthy Indian infants were randomized (2:1) to receive either Shantetra or Tritanrix HBTM.
  • Humoral immune response, specifically seroconversion rates for each antigenic component, was monitored post-vaccination.

Main Results:

  • Shantetra demonstrated high seroprotective rates: 98.9% for diphtheria, tetanus, and hepatitis B components.
  • Anti-pertussis antibody response was robust, observed in 89% of infants receiving Shantetra.
  • Common adverse events, including injection site pain, mild fever, and transient crying, were similar in both vaccine groups.

Conclusions:

  • The indigenously developed DTPw-Hepatitis B combination vaccine (Shantetra) is safe and immunogenic in healthy Indian infants.
  • Shantetra provides comparable seroprotective immune responses to the comparator vaccine.
  • This study supports the use of indigenously developed vaccines for national immunization programs.
Abstract

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...